



TRANSMITTAL LETTER
(General - Patent Pending)

Docket No.
01160/1/US (PC27544) *TJm*

Application Of: Timothy J. Hagen et al.

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/623,228	July 18, 2003	Laura L. Stockton	26648	1626	2720

Title: SUBSTITUTED THIOPHENE CARBOXAMIDE COMPOUNDS FOR THE TREATMENT OF INFLAMMATION

COMMISSIONER FOR PATENTS:

Transmitted herewith is:

Amendment Transmittal; Response to Notice of Non-Compliant Amendment; Itemized Postcard.

in the above identified application.

- No additional fee is required.
- A check in the amount of _____ is attached.
- The Director is hereby authorized to charge and credit Deposit Account No. 19-1025 as described below.
 - Charge the amount of _____
 - Credit any overpayment.
 - Charge any additional fee required.
- Payment by credit card. Form PTO-2038 is attached.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Patricia K. Fitzsimmons
Signature

Dated: August 22, 2005

Patricia K. Fitzsimmons, Reg. No. 52,894
Pharmacia Corporation of Pfizer Inc.
P.O. Box 1027
Chesterfield, Missouri 63006
314.274.1490

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on

8/22/05

(Date)

Linda K. Cooper
Signature of Person Mailing Correspondence

Typed or Printed Name of Person Mailing Correspondence

CC:

AMENDMENT TRANSMITTAL LETTER (Large Entity)

Applicant(s): Timothy J. Hagen et al.

Docket No.

01160/1/US(PC27544)

Application No.
10/623,228Filing Date
July 18, 2003Examiner
Laura L. StocktonCustomer No.
26648Group Art Unit
1626Confirmation No.
2720

P E
 Invention: SUBSTITUTED THIOPHENE CARBOXAMIDE COMPOUNDS FOR THE TREATMENT OF
 INFLAMMATION

AUG 25 2005

COMMISSIONER FOR PATENTS:

Transmitted herewith is an amendment in the above-identified application.

The fee has been calculated and is transmitted as shown below.

CLAIMS AS AMENDED

	CLAIMS REMAINING AFTER AMENDMENT	HIGHEST # PREV. PAID FOR	NUMBER EXTRA CLAIMS PRESENT	RATE	ADDITIONAL FEE
TOTAL CLAIMS	13 -	69 =	0	x \$50.00	\$0.00
INDEP. CLAIMS	1 -	1 =	0	x \$200.00	\$0.00
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>					\$0.00
TOTAL ADDITIONAL FEE FOR THIS AMENDMENT					\$0.00

- No additional fee is required for amendment.
- Please charge Deposit Account No. _____ in the amount of _____.
- A check in the amount of _____ to cover the filing fee is enclosed.
- The Director is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account 19-1025
 - Any additional filing fees required under 37 C.F.R. 1.16.
 - Any patent application processing fees under 37 CFR 1.17.
- Payment by credit card. Form PTO-2038.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Patricia K. Fitzsimmons
Signature

Dated: August 22, 2005

Patricia K. Fitzsimmons, Reg. No. 52,894
 Pharmacia Corporation of Pfizer Inc.
 P.O. Box 1027
 Chesterfield, Missouri 63006
 314.274.1490

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on

August 22, 2005

(Date)

Linda K. Cooper
Signature of Person Mailing Correspondence

Linda K. Cooper

Typed or Printed Name of Person Mailing Correspondence

CC:



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Hagen et al.) GROUP ART UNIT: 1626
)
SERIAL NO.: 10/623,228) CONFIRMATION NO.: 2720
)
EXAMINER: Stockton) ATTORNEY DOCKET NO.: 01160/1/US
)
FILED: July 18, 2003) (PC27544)

TITLE: SUBSTITUTED THIOPHENE CARBOXAMIDE COMPOUNDS FOR THE
 TREATMENT OF INFLAMMATION

CERTIFICATE OF MAILING

I hereby certify that this communication and any recited enclosures are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on **August 22, 2005**.

Linda K. Cooper
Linda K. Cooper

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

August 22, 2005
(first business day after August 21, 2005)

RESPONSE TO NOTICE OF NON-COMPLIANT AMENDMENT

Sir:

In response to the Notice of Non-Compliant Amendment of July 21, 2005, Applicants submit the following corrected Listing of Claims.

Amendments to the Claims are reflected in the listing of claims that begins on page 2 of this paper.

Remarks/Arguments begin on page 15 of this paper.